文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

黄病毒:从结构到治疗药物研发

Flavivirus: From Structure to Therapeutics Development.

作者信息

Zhao Rong, Wang Meiyue, Cao Jing, Shen Jing, Zhou Xin, Wang Deping, Cao Jimin

机构信息

Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.

Department of Physiology, Shanxi Medical University, Taiyuan 030001, China.

出版信息

Life (Basel). 2021 Jun 25;11(7):615. doi: 10.3390/life11070615.


DOI:10.3390/life11070615
PMID:34202239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8303334/
Abstract

Flaviviruses are still a hidden threat to global human safety, as we are reminded by recent reports of dengue virus infections in Singapore and African-lineage-like Zika virus infections in Brazil. Therapeutic drugs or vaccines for flavivirus infections are in urgent need but are not well developed. The Flaviviridae family comprises a large group of enveloped viruses with a single-strand RNA genome of positive polarity. The genome of flavivirus encodes ten proteins, and each of them plays a different and important role in viral infection. In this review, we briefly summarized the major information of flavivirus and further introduced some strategies for the design and development of vaccines and anti-flavivirus compound drugs based on the structure of the viral proteins. There is no doubt that in the past few years, studies of antiviral drugs have achieved solid progress based on better understanding of the flavivirus biology. However, currently, there are no fully effective antiviral drugs or vaccines for most flaviviruses. We hope that this review may provide useful information for future development of anti-flavivirus drugs and vaccines.

摘要

正如新加坡近期登革热病毒感染报告以及巴西出现的类似非洲谱系的寨卡病毒感染所提醒我们的那样,黄病毒仍然是全球人类安全的潜在威胁。目前迫切需要针对黄病毒感染的治疗药物或疫苗,但相关研发进展并不理想。黄病毒科包含一大类包膜病毒,其基因组为单链正链RNA。黄病毒的基因组编码十种蛋白质,每种蛋白质在病毒感染过程中都发挥着不同且重要的作用。在这篇综述中,我们简要总结了黄病毒的主要信息,并基于病毒蛋白的结构进一步介绍了一些疫苗和抗黄病毒复合药物的设计与开发策略。毫无疑问,在过去几年里,基于对黄病毒生物学的更深入了解,抗病毒药物研究取得了坚实进展。然而,目前对于大多数黄病毒而言,尚无完全有效的抗病毒药物或疫苗。我们希望这篇综述能为未来抗黄病毒药物和疫苗的研发提供有用信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/e9f275804322/life-11-00615-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/a9550e1bdf8d/life-11-00615-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/19f609734017/life-11-00615-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/eff8033cd47d/life-11-00615-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/600a0804a4dc/life-11-00615-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/e9f275804322/life-11-00615-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/a9550e1bdf8d/life-11-00615-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/19f609734017/life-11-00615-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/eff8033cd47d/life-11-00615-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/600a0804a4dc/life-11-00615-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72b/8303334/e9f275804322/life-11-00615-g005.jpg

相似文献

[1]
Flavivirus: From Structure to Therapeutics Development.

Life (Basel). 2021-6-25

[2]
Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics.

Vet Res. 2021-6-30

[3]
Establishment and Application of Flavivirus Replicons.

Adv Exp Med Biol. 2018

[4]
Zika Virus Subgenomic Flavivirus RNA Generation Requires Cooperativity between Duplicated RNA Structures That Are Essential for Productive Infection in Human Cells.

J Virol. 2020-8-31

[5]
An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

J Virol. 2017-11-14

[6]
Zika virus structural biology and progress in vaccine development.

Biotechnol Adv. 2017-9-12

[7]
Therapeutics for flaviviral infections.

Antiviral Res. 2023-2

[8]
Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses.

Prog Lipid Res. 2016-10-1

[9]
Development of Antibody Therapeutics against Flaviviruses.

Int J Mol Sci. 2017-12-25

[10]
Rewiring cellular networks by members of the Flaviviridae family.

Nat Rev Microbiol. 2018-2-12

引用本文的文献

[1]
Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections.

Front Immunol. 2025-7-16

[2]
Deciphering the Code of Viral-Host Adaptation Through Maximum-Entropy Nucleotide Bias Models.

Mol Biol Evol. 2025-6-4

[3]
From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.

Vaccines (Basel). 2025-4-24

[4]
LncRNA regulates GRP78 and DDX5 axis to promote JEV infection and cell death.

J Virol. 2025-5-20

[5]
Advancements in Antimicrobial Textiles: Fabrication, Mechanisms of Action, and Applications.

ACS Omega. 2025-3-28

[6]
Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors.

Pharmaceuticals (Basel). 2025-2-20

[7]
Characterization of Novel Plantaricin-Derived Antiviral Peptides Against Flaviviruses.

Int J Mol Sci. 2025-1-25

[8]
Transient Expression of Zika NS2B Protein Antigen in and Use for Arboviruses Diagnosis.

ACS Omega. 2025-1-8

[9]
Viral-host molecular interactions and metabolic modulation: Strategies to inhibit flaviviruses pathogenesis.

World J Virol. 2024-12-25

[10]
Dengue Virus Infection: Immune Response and Therapeutic Targets.

Am J Trop Med Hyg. 2024-11-12

本文引用的文献

[1]
Identification of potential inhibitors of Zika virus NS5 RNA-dependent RNA polymerase through virtual screening and molecular dynamic simulations.

Saudi Pharm J. 2020-12

[2]
Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction.

Science. 2021-1-8

[3]
A broadly protective antibody that targets the flavivirus NS1 protein.

Science. 2021-1-8

[4]
Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.

Cell Rep Med. 2020-12-22

[5]
The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study.

Vaccines (Basel). 2020-11-12

[6]
Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection.

Front Cell Infect Microbiol. 2020

[7]
High flavivirus structural plasticity demonstrated by a non-spherical morphological variant.

Nat Commun. 2020-6-19

[8]
A recursive sub-typing screening surveillance system detects the appearance of the ZIKV African lineage in Brazil: Is there a risk of a new epidemic?

Int J Infect Dis. 2020-6-1

[9]
Capsid protein is central to the birth of flavivirus particles.

PLoS Pathog. 2020-5-28

[10]
Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture.

Hum Vaccin Immunother. 2020-9-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索